Prostate-specific-antigen testing for early diagnosis of prostate cancer

New England Journal of Medicine

Volumn 344, Issue 18, 2001, Pages 1373-1377

  Barry, Michael J ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CASE REPORT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; MALE; MORTALITY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE CANCER; UNITED STATES; BIOPSY; BLOOD; MASS SCREENING; MIDDLE AGED; PRACTICE GUIDELINE; PROSTATE TUMOR; REVIEW;

AGED; BIOPSY; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PHYSICAL EXAMINATION; PRACTICE GUIDELINES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0035799768     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200105033441806     Document Type: Article

References (37)

1. SEER cancer statistics review, 1973-1997
2. Comparison of trends in prostate-cancer mortality in England and Wales and the USA
3. Prostate specific antigen kinetics: A review of prostate specific antigen doubling times and half-lives in patients with treated and untreated prostate cancer
4. Cancer statistics 2000
5. Ejaculation increases the serum prostate-specific antigen concentration
6. Effect of ejaculation on serum total and free prostate-specific antigen concentrations
7. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels
8. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer
9. Serum prostate-specific antigen discriminates weakly between men with benign prostatic hyperplasia and patients with organ-confined prostate cancer
10. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination
11. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: Enhancement of specificity with free PSA measurements
12. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial
13. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. prostate specific antigen
14. Optimal predictors of prostate cancer on repeat prostate biopsy: A prospective study of 1,051 men
15. Extended field prostate biopsy enhances cancer detection
16. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng./ml.: Relation to biopsy strategy
17. Lowering PSA cutoffs to enhance detection of curable prostate cancer
18. A PSA threshold of 4.0 ng/mL for early detection of prostate cancer: The only rational approach for men 50 years old and older
19. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men
20. Optimal predictors of prostate cancer on repeat prostate biopsy: A prospective study of 1,051 men
21. Extended field prostate biopsy enhances cancer detection
22. Extended field prostate biopsies: Too much of a good thing?
23. PSAdynia and other PSA-related syndromes: A new epidemic - A case history and taxonomy
24. Prostate cancer screening and beliefs about treatment efficacy: A national survey of primary care physicians and urologists
25. Prostate specific antigen: A decade of discovery - What we have learned and where we are going
26. A comparison of six commercial assays for total and free prostate specific antigen (PSA): The predictive value of the ratio of free to total PSA
27. Prostate-specific antigen testing for early diagnosis of prostate cancer: Formulation of guidelines
28. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection
29. Screening decreases prostate cancer death: First analysis of the 1988 Quebec prospective randomized controlled trial
30. Quebec randomized controlled trial on prostate cancer screening shows no evidence for mortality reduction
31. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer
32. Screening for prostate cancer
33. American Cancer Society guidelines for the early detection of cancer: Update of early detection guidelines for prostate, colorectal, and endometrial cancers
34. Screening for prostate cancer
35. Prostate-specific antigen (PSA) best practice policy
36. What should men know about prostate-specific antigen screening before giving informed consent?
37. Decision-aids for prostate cancer screening